A clinical trial led by MUSC and Emory University tested opaganib, a first-in-class experimental drug, on men with treatment-resistant advanced prostate cancer.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Experimental drug shows promise for some patients with advanced prostate cancer
First-In-Class Therapy Drug type
Sphingolipid Metabolism Pathway Target
Metastatic Castration-Resistant Prostate Cancer Cancer type